The U.S. Army Medical Research and Development Command (USAMRDC) selected EIDB’s COVID vaccine candidate, Spike Ferritin Nanoparticle (SpFN), as one of the 2020 award recipients. This years’ award was jointly given to the Army-developed and patented adjuvant, Army Liposome Formulation with QS21 (ALFQ), which is used in the SpFN vaccine
EIDB and partners in Nigeria will participate in Coalition for Epidemic Preparedness Innovations (CEPI) and European & Developing Countries Clinical Trials Partnership (EDCTP) funded Phase II and III clinical trials of IAVI's Lassa fever vaccine candidate later this year.
A unique vaccine to protect against COVID-19 begins Phase 1 clinical testing in early April at the at the Walter Reed Army Institute of Research (WRAIR) Clinical Trials Center. Scientists developed a nanoparticle vaccine based on a ferritin platform that offers a flexible approach to target multiple variants of SARS-COV-2 and potentially other coronaviruses as well
Dr. Michael Iroezindu was always interested in a career in the science field. He says, “growing up, I realized that science provided me with more stimulating and objective pathways to address my curiosities.” After having two siblings pursue medical careers, he decided to do the same.
EIDB announced the selection of a lead COVID-19 vaccine candidate as well as two backup vaccine candidates that will advance to the next stage of research. The vaccine is based on a Spike Ferritin Nanoparticle platform and is called SpFN.
Genetic analysis of sequences from more than 27,000 individuals infected with the coronavirus that causes COVID-19 reveals that the virus has mutated minimally since December 2019, suggesting one vaccine would be sufficient to combat global infections.
